Preview
Description
A Multicenter, Randomized, Phase 3 Study Comparing LY3537982 and Pembrolizumab to Placebo and Pembrolizumab as First-Line Treatment in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression (TPS ≥ 50%). This app is specifically intended for participants in the J3M-MC-JZQB study only.
What's New
Version 5.4.1101 2025-11-21
This update includes improvements and bug fixes to enhance your experience. Technical Analysis
Package Overview Basic metadata
Bundle ID
com.medable.lilly-jzqb-patient Current Version 5.4.1101
Minimum iOS 14.0
Package Size App Store Size
Package Metadata 0 / 3 version records
Detailed binary, privacy manifest, framework, and Info.plist results have not been indexed for this package yet. The verified App Store and archive metadata above remains available.
Developer Information
Known Version Records
0 version records with stored package metadata • 3 known version records
Stored metadata does not guarantee a package is currently available to download.
| Details | Version / IDs | Version date | Action |
|---|---|---|---|
| Not archived | App Store ID: 876705374 | Unknown | Request Version |
| Not archived | App Store ID: 869400341 | Unknown | Request Version |
| Not archived | App Store ID: 859168891 | Unknown | Request Version |